Literature DB >> 26893495

Implantable cardioverter defibrillator therapy in young individuals: comparison of conventional and subcostal approaches-a single-centre experience.

Ghazala Irfan1, Jens Czapla2, Yukio Saitoh3, Giuseppe Ciconte3, Giacomo Mugnai3, Giulio Conte3, Burak Hunuk3, Vedran Velagic3, Erwin Stroker3, Gian Battista Chierchia3, Jan Nijs2, Marc La Meir2, Francis Wellens2, Pedro Brugada3, Carlo De Asmundis3.   

Abstract

AIM: The aim of our study is to compare two approaches of implantable cardiac defibrillator (ICD) implantation, conventional (supra/subpectoral) and subcostal in young adults in terms of procedural complications and adverse events encountered during follow-up. METHODS AND
RESULTS: From January 2007 to December 2013, all patients under the age of 50 years who received an ICD in our centre were included in this study. Patient's hospital records were analysed for procedural complications and adverse events during follow-up until December 2014. Data from device on first interrogation after implantation and on follow-up were also noted. A total of 106 patients of which 40.6% had Brugada's syndrome (65.1% male, age 33.6 ± 10.97 years) were included in analysis; 71 (61%) had ICD placed in (sub/supra) pectoral and 35 (33%) in subcostal position. Only seven patients received an epicardial lead system. During the follow-up period of 2.1 ± 1.8 years, 84.90% of the patients had no adverse events. Most of the complications, procedural and during follow-up, occur in conventionally placed, pectoral ICD. Lead follow-up data in both groups, conventional and subcostal, showed no difference in right ventricular (RV) shock impedance and R wave sensing, P-value = 0.56 and 0.77, respectively. Lead survival was 95 and 97%, respectively, in conventional and subcostal groups over a mean follow-up of 2.1 ± 1.8 years. Log-rank test for lead survival was not significant in terms of site of implantation.
CONCLUSION: To the best our knowledge, this is the first study demonstrating subcostal ICD placement in young adults and resulting in equivalent to better outcomes when compared with conventionally placed pectoral ICD. Subcostal ICD placement might be considered an alternative option in young adults as it results in better procedural outcomes and also comparable rate of adverse events during follow-up, but bigger studies with a larger number of patients are needed for a definitive conclusion. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac device complications; Implantable cardioverter defibrillator; Implantation technique; Lead failure; Subcostal ICD

Mesh:

Year:  2016        PMID: 26893495     DOI: 10.1093/europace/euv455

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

1.  Clinical outcome of patients with the Brugada type 1 electrocardiogram without prophylactic implantable cardioverter defibrillator in primary prevention: a cumulative analysis of seven large prospective studies.

Authors:  Pietro Delise; Vincent Probst; Giuseppe Allocca; Nadir Sitta; Luigi Sciarra; Josep Brugada; Shiro Kamakura; Masahiko Takagi; Carla Giustetto; Leonardo Calo
Journal:  Europace       Date:  2018-06-01       Impact factor: 5.214

2.  Concomitant Brugada syndrome substrate ablation and epicardial abdominal cardioverter-defibrillator implantation in a child.

Authors:  Carlo de Asmundis; Gian Battista Chierchia; Giannis G Baltogiannis; Francesca Salghetti; Juan Sieira; Theofilos M Kolettis; Kassiani Tasi; Antonios Vlahos; Jens Czapla; Pedro Brugada; Mark La Meir
Journal:  HeartRhythm Case Rep       Date:  2018-03-17

Review 3.  Brugada syndrome: A comprehensive review of pathophysiological mechanisms and risk stratification strategies.

Authors:  Ka Hou Christien Li; Sharen Lee; Chengye Yin; Tong Liu; Tachapong Ngarmukos; Giulio Conte; Gan-Xin Yan; Raymond W Sy; Konstantinos P Letsas; Gary Tse
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.